Literature DB >> 15668785

IgA nephropathy in association with Crohn's disease.

M J Forshaw1, O Guirguis, T W Hennigan.   

Abstract

BACKGROUND: Urological complications of inflammatory bowel disease are seen in up to 25% of patients, but renal parenchymal disease is rarely reported. CASE REPORT: The authors describe a case of a 29-year-old man with clinical and radiological features of ileocaecal Crohn's disease. He had previously been investigated for painless macroscopic haematuria and a renal biopsy had revealed IgA nephropathy. Despite medical treatment, regular exacerbations of Crohn's disease were associated with deterioration in renal function and the development of haematuria. The patient eventually underwent surgical resection of the terminal ileum and caecum. His renal disease has remained quiescent for the last 5 years following resection.

Entities:  

Mesh:

Year:  2005        PMID: 15668785     DOI: 10.1007/s00384-004-0696-z

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  18 in total

Review 1.  Treatment of IgA nephropathy.

Authors:  B A Julian
Journal:  Semin Nephrol       Date:  2000-05       Impact factor: 5.299

2.  [Crohn's disease associated with Berger's disease. A rare complication].

Authors:  J M López Barbarín; P Lafuente Martínez; F García Campos; B Ibarra Peña; R Díaz de Otazu
Journal:  Rev Esp Enferm Dig       Date:  1990-10       Impact factor: 2.086

3.  IgA nephropathy and thin basement membrane disease in association with Crohn disease.

Authors:  D McCallum; L Smith; F Harley; V Yiu
Journal:  Pediatr Nephrol       Date:  1997-10       Impact factor: 3.714

4.  Predicting renal outcome in IgA nephropathy.

Authors:  M G Radford; J V Donadio; E J Bergstralh; J P Grande
Journal:  J Am Soc Nephrol       Date:  1997-02       Impact factor: 10.121

5.  Evidence suggesting the involvement of hematopoietic stem cells in the pathogenesis of IgA nephropathy.

Authors:  T Imasawa; Y Utsunomiya; T Kawamura; R Nagasawa; N Maruyama; O Sakai
Journal:  Biochem Biophys Res Commun       Date:  1998-08-28       Impact factor: 3.575

6.  Distinct associations of HLA class II genes with inflammatory bowel disease.

Authors:  H Toyoda; S J Wang; H Y Yang; A Redford; D Magalong; D Tyan; C K McElree; S R Pressman; F Shanahan; S R Targan
Journal:  Gastroenterology       Date:  1993-03       Impact factor: 22.682

7.  Monoamine oxidase inhibitors for IgA nephropathy.

Authors:  E L Altschuler
Journal:  Med Hypotheses       Date:  2001-02       Impact factor: 1.538

Review 8.  The immunological and genetic basis of inflammatory bowel disease.

Authors:  Gerd Bouma; Warren Strober
Journal:  Nat Rev Immunol       Date:  2003-07       Impact factor: 53.106

9.  Increased intestinal permeability to (51 Cr) EDTA is correlated with IgA immune complex-plasma levels in children with IgA-associated nephropathies.

Authors:  J C Davin; P Forget; P R Mahieu
Journal:  Acta Paediatr Scand       Date:  1988-01

10.  HLA associations in IgA nephropathy and focal and segmental glomerulosclerosis.

Authors:  B I Freedman; B J Spray; E R Heise
Journal:  Am J Kidney Dis       Date:  1994-03       Impact factor: 8.860

View more
  13 in total

1.  Infliximab treatment in two patients with psoriatic arthritis and secondary IgA nephropathy.

Authors:  Grigorios T Sakellariou; Periklis Vounotrypidis; Charalampos Berberidis
Journal:  Clin Rheumatol       Date:  2006-08-19       Impact factor: 2.980

2.  Adalimumab-induced IgA nephropathy.

Authors:  Aneesha Kaur Bhagat Singh; Andrew Sujeevan Jeyaruban; Gregory John Wilson; Dwarakanathan Ranganathan
Journal:  BMJ Case Rep       Date:  2019-03-31

3.  Recurrent IgA nephropathy complicated with Crohn's disease after renal transplantation.

Authors:  Midori Hasegawa; Hitomi Sasaki; Kazuo Takahashi; Hiroki Hayashi; Shigehisa Koide; Makoto Tomita; Asami Takeda; Kiyotaka Hoshinaga; Yukio Yuzawa
Journal:  CEN Case Rep       Date:  2014-02-16

4.  Infliximab treatment for Crohn's disease in a patient with IgA nephropathy.

Authors:  Yoshitaka Ueno; Shinji Tanaka; Toshiko Onitake; Rie Hanaoka; Kyoko Yoshioka; Masanori Ito; Kazuaki Chayama
Journal:  Clin J Gastroenterol       Date:  2009-10-03

5.  Differentiation of T Helper 17 Cells May Mediate the Abnormal Humoral Immunity in IgA Nephropathy and Inflammatory Bowel Disease Based on Shared Genetic Effects.

Authors:  Jianbo Qing; Changqun Li; Xueli Hu; Wenzhu Song; Hasna Tirichen; Hasnaa Yaigoub; Yafeng Li
Journal:  Front Immunol       Date:  2022-06-13       Impact factor: 8.786

6.  The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease.

Authors:  Josephine M Ambruzs; Patrick D Walker; Christopher P Larsen
Journal:  Clin J Am Soc Nephrol       Date:  2013-11-21       Impact factor: 8.237

7.  The possible involvement of intestine-derived IgA1: a case of IgA nephropathy associated with Crohn's disease.

Authors:  Tomohiro Terasaka; Haruhito A Uchida; Ryoko Umebayashi; Keiko Tsukamoto; Keiko Tanaka; Masashi Kitagawa; Hitoshi Sugiyama; Hiroaki Tanioka; Jun Wada
Journal:  BMC Nephrol       Date:  2016-09-05       Impact factor: 2.388

8.  A case of rapidly progressive IgA nephropathy in a patient with exacerbation of Crohn's disease.

Authors:  Ji-Young Choi; Chung Hoon Yu; Hee-Yeon Jung; Min Kyu Jung; Yong-Jin Kim; Jang-Hee Cho; Chan-Duck Kim; Yong-Lim Kim; Sun-Hee Park
Journal:  BMC Nephrol       Date:  2012-08-06       Impact factor: 2.388

9.  Paraneoplastic immunoglobulin A nephropathy and associated focal segmental glomerulosclerosis in asymptomatic low volume B-cell lymphoma - a case report.

Authors:  Monica Suet Ying Ng; Leo Francis; Elango Pillai; Andrew John Mallett
Journal:  BMC Nephrol       Date:  2018-09-10       Impact factor: 2.388

10.  Renal involvement in children and adolescents with inflammatory bowel disease.

Authors:  Hea Min Jang; Hee Sun Baek; Jung-Eun Kim; Ju Young Kim; Yeon Hee Lee; Hee Yeon Cho; Yon Ho Choe; Ben Kang; Byung-Ho Choe; Bong Seok Choi; Min Hyun Cho
Journal:  Korean J Pediatr       Date:  2018-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.